![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
Lung cancer continues to be a leading cause of cancer-related deaths in Hong Kong, with non-small cell lung cancer (NSCLC) accounting for about 82% of cases in 2021. Recent findings from the World Conference on Lung Cancer (WCLC) 2024, highlight promising advancements in the treatment of advanced NSCLC (aNSCLC).
Lung cancer remains a leading cause of cancer-related deaths worldwide. Advances in targeted therapies improving the outcome for lung cancer patients were highlighted at the ASCO 2024 conference. A summary of clinical data, focusing on novel treatment options and new combination-therapies.
There is no excerpt because this is a protected post.
Severe COVID-19 infection does not only bring about patient distress, but also increases public health expenditure in supportive devices such as ventilators. It is necessary to minimise the risk of COVID-19 infection in cancer patients, considering COVID-19 waves are likely to recur regularly and they are the high-risk groups. Personal hygiene measures and COVID-19 vaccination have been demonstrated to be efficacious and should be recommended to cancer patients for lowering the likelihood of hospitalisation, ICU admission and mortality.
Lung cancer is one of the leading cancers in Hong Kong, accounting for 26.4% of cancer mortality in 2018. Approximately 80% of the lung cancers are non-small cell lung cancer (NSCLC).
Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer. The most frequent genetic mutation harboured in lung adenocarcinomas occurs in the epidermal growth factor receptor (EGFR), accounting for 40-55% in Asian patients.
With the World Conference on Lung Cancer (WCLC) 2020 completed last January, several new and clinical relevant phase 2 and phase 3 studies on Lung Cancer have been published. We summarised some key data for you.
Lung cancer is a leading cause of cancer-related death. In East Asian non-small cell lung cancer (NSCLC) patients, epidermal growth factor receptor (EGFR) mutations occur in 40-55% of lung adenocarcinomas.
Women account for a disproportionate percentage of new human immunodeficiency virus (HIV) infections in sub-Saharan Africa, comprising 59% of 18 million new adult HIV infections in 2017.
Kidney transplants are the best treatment for end-stage renal disease (ESRD), with better survival outcomes than haemodialysis or peritoneal dialysis. However, in Hong Kong as well as much of the rest of the world, there is an increasing gap between the number of patients requiring a transplant and the number of organs available.